Breast Cancer
Conditions
Keywords
Tapentadol, Breast Cancer Surgery, Morphine
Brief summary
This study evaluated the preemptive analgesic efficacy of Tapentadol in reducing peri operative analgesic requirements among patients undergoing breast cancer surgery.
Detailed description
A double blinded prospective RCT was conducted with 70 patients undergoing breast cancer surgery with 35 patients being studied with Administrated drug & other 35 as placebo. Intraoperative & postoperative morphine consumption was calculated and documented.
Interventions
DRUGTapentadol
75 mg oral tapentadol given 1 hour before surgery in control group and placebo tablet was given in Group B. Intraoperative and post operative morphine consumption and pain scores at 1,2,3,4 hours were calculated.
OTHERPlacebo
Placebo tablet was given in group B.
Sponsors
Shaukat Khanum Memorial Cancer Hospital & Research Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)
Masking description
The patient and doctor providing anesthesia were blinded.
Intervention model description
Randomized control trial
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. 18-60 years 2. ASA 1,2,3 3. Patients scheduled for breast conservation surgery -
Exclusion criteria
1. Patient refusal 2. CKD greater than 3 3. BMI greater than 35 4. Known drug allergy -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intraoperative and postoperative morphine consumption | During the course of surgery and up to 4 hours surgery | During the course of surgery and up to 4 hours surgery Intraoperative and postoperative morphine consumption. |
Countries
Pakistan
Outcome results
None listed